A study comparing COVID-19 patients to pre-pandemic subjects found that COVID-19 survivors had lower levels of fT3 and fT4, higher TSH and aTPO antibodies, and higher levels of prolactin and testosterone. However, no significant differences were found in body composition or metabolic and glycemic parameters between cases and controls. The study suggests that SARS-CoV-2 infection may have long-term consequences on the endocrine system, including suppressed thyroid gland function, prolactin, and male sex hormone secretion. However, COVID-19 had no significant impact on glycemic parameters, lipid profiles, liver function, body composition, cortisol levels, and estradiol levels. Long-term effects of COVID-19 on the endocrine system - a pilot case-control study - PubMed (nih.gov)
*****************
A study examining the natural history, symptomology, and risk profile of long-term post-acute SARS-CoV-2 fatigue in US patients found that those with severe fatigue were younger, female, had more anxiety and depression, had a higher resting heart rate, reported more sick days, and were less physically active post-COVID. They were more likely to have a diagnosis of chronic kidney disease but less likely to have a history of cancer. Fatigue was significantly correlated with impairment of all PROs administered after COVID-19 infection. Severe, Persistent, Disruptive Fatigue Post-SARS-CoV-2 Disproportionately Affects Young Women - PubMed (nih.gov)
*****************
A study involving 113 UK Armed Forces participants found that COVID-19 infection can lead to a prolonged syndrome including fatigue, exercise intolerance, mood, and cognitive problems. The study found that at 5 and 12 months, exposed participants had higher PHQ-9, PCL-5, and FAS scores than controls. However, by 18 months, GAD-7 was not significantly different to controls. The study also found that exposed participants recorded significantly lower distances on the 6-minute walk test. The study concluded that COVID-19 exposure improved cognitive performance and depression up to 12 months. How long is Long-COVID? Symptomatic improvement between 12 and 18 months in a prospective cohort study - PubMed (nih.gov)
*****************
A study by CO-FLOW aimed to evaluate the long-term consequences of COVID-19 on return to work and health-related quality of life (HRQoL) in adult patients up to one year after hospitalization. The study involved 371 participants and collected data at 3, 6, and 12 months post-discharge. Results showed that 50% of participants had not returned to work, and 15% only partially returned. Factors such as ICU admission, persistent fatigue, female sex, and older age were independently associated with no return to work. The study concluded that only 69% of patients fully returned to work one year after hospitalization, with 15% not returning and 16% partially returning. Return to work and health-related quality of life up to 1 year in patients hospitalized for COVID-19: the CO-FLOW study - PubMed (nih.gov)
*****************
Research indicates that SARS-CoV-2 infection may cause gut dysbiosis, affecting the gut-lung axis and reducing antimicrobial peptide production. Studies show a decline in alpha diversity and increased dissimilarity in beta diversity of gut microbiota during COVID-19, leading to heightened inflammation in patients. This is linked to the severity of the disease and post-acute COVID-19 syndrome. Certain gut microbiota species could aid in diagnosis, prediction, and treatment of severe cases. Profiles of gut microbiota associated with clinical outcomes in patients with different stages of SARS-CoV-2 infection - PubMed (nih.gov)

Comments
Post a Comment